stock-detail (ATRA)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/23/2017 12:17 pm

4/23/2017 12:17 pm

4/23/2017 12:17 pm

4/21/2017 06:17 am

4/21/2017 06:17 am

Atara Bio Expands Management Team, Appoints Joe Newell as Executive Vice President, Chief Technical Operations Officer

4/3/2017 12:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., April 03, 2017-- Atara Biotherapeutics, Inc., a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been ...

Atara Bio's Collaborating Investigators to Present Interim Results from Phase 1 Trial of the Autologous Version of ATA188 in Patients with Progressive Multiple Sclerosis (MS)

3/17/2017 04:04 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., March 17, 2017-- Atara Biotherapeutics, Inc., a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that ...

Atara Bio Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights

3/9/2017 01:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., March 09, 2017-- Atara Biotherapeutics, Inc., a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been ...

Atara Bio to Present at the 35th Annual J.P. Morgan Healthcare Conference

1/4/2017 01:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., Jan. 04, 2017-- Atara Biotherapeutics, Inc., a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been ...

Atara Bio Concludes EMA Scientific Advice and Plans to Submit Conditional Marketing Authorization Application (MAA) in Europe for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, for the Treatment of E

1/3/2017 01:01 pm

[at noodls] - SOUTH SAN FRANCISCO, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening ...

Atara Bio Concludes EMA Scientific Advice and Plans to Submit Conditional Marketing Authorization Application (MAA) in Europe for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, for the Treatment of E

1/3/2017 01:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., Jan. 03, 2017-- Atara Biotherapeutics, Inc., a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been ...

Atara Bio Reaches Agreement with FDA on Design of Phase 3 Trials for its Lead Anti-Cancer Immunotherapy Program, Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, to Support Potential Approval in Two Se

12/12/2016 01:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., Dec. 12, 2016-- Atara Biotherapeutics, Inc., a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, ...

Atara Bio Announces Results from Ongoing Phase 2 Trial of Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) at the American Society of Hematology (ASH) Annual Meeting 2016

12/3/2016 03:03 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., Dec. 03, 2016-- Atara Biotherapeutics, Inc., a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have ...